Defining the minimal clinically meaningful improvement (MCMI) is crucial to understanding the treatment effects on health-status measures. We estimated the MCMI on the quality of erection questionnaire (QEQ), a validated measure specific to assess erectile quality during sexual intercourse. Data were from two controlled trials of an investigational phosphodiesterase type 5 inhibitor. Improvement on the Erectile Function domain of the International Index of Erectile Function was used as the anchor. For men who improved by exactly 1 erectile dysfunction severity category (anchor group (n ¼ 95)), clinically meaningful improvement (CMI, estimated with mean QEQ total change score from baseline to end of treatment) and MCMI (estimated with the lower limit of the 95% confidence interval of the mean) were 22.4 (s.d., 2.2) and 18.0 points, respectively. For the difference between the anchor group and men with no change in severity category (n ¼ 116), CMI and MCMI were 17.7 (s.d., 2.9) and 12 points, respectively. Distribution-based analyses (baseline s.e. of measurement (s.e.m.) ¼ 7.99, end-of-treatment s.e.m. ¼ 8.22 and s.e. of difference ¼ 11.46) supported a proposed MCMI of 12 points. Convergence of anchor-based and distribution-based criteria supports at least a 12-point difference in QEQ scores between treatments as clinically important.
Introduction
The quality of erection questionnaire (QEQ) is a new six-item patient-reported outcome (PRO) for evaluating the quality of erections in terms of hardness, onset, and duration, as well as for assessing changes in erection quality with successful treatment of erectile dysfunction (ED) (Tables 1a and 1b) . 1, 2 Although the past decade has seen the development of many PROs to evaluate ED, 3 the QEQ is unique in that it is the only psychometrically validated assessment tool designed to solely and specifically evaluate satisfaction with the quality of erections. 2, 3 The development and validation of the QEQ were described previously. 2 In prospective trials of flexible-dose sildenafil citrate (25, 50 or 100 mg) for the treatment of men with ED, the mean ± s.d. transformed QEQ total score increased by more than 40 points, from baseline values of 22 1 and 34 4 points, in men treated with sildenafil. Furthermore, the QEQ had convergent validity with measures of sexual function (International Index of Erectile Function (IIEF) 5, 6 ), erection hardness (Erection Hardness Score 7 ), satisfaction (Erectile Dysfunction Inventory of Treatment Satisfaction 8 ) and emotional well-being (Self-Esteem And Relationship Questionnaire (SEAR) 9, 10 ). 1, 4 Health-status measures have become a standard and essential part of validated PROs in many different types of diseases. However, to understand the relevance of outcomes on a health-status measure, it is crucial to be able to interpret the scores and have established criteria for determining the meaningfulness of changes in scores. Such an understanding is important, not only in helping complete a psychometric evaluation, but also in designing trials, evaluating interventions, informing consumers and health policy makers, and providing information for formulary and reimbursement decisions. 11, 12 The importance of determining the minimum important difference threshold is highlighted by the inclusion of a discussion in the US Food and Drug Administration's draft guidance for industry, 'Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims'. 13 For a new PRO instrument, clinically meaningful change can be estimated using an anchor-based approach in which change on the new instrument is compared with change in disease status. Assessing change in disease status in some areas such as sexual health must be through self-report by the patient. In this case, a known disease-related measure that has clinical relevance and has an appreciable association with the targeted healthstatus measure can be used. 11, 14 Another approach relies on the statistical characteristics of a study sample-a distribution-based approach 11, 14, 15 which can be used to attempt to corroborate estimates from an anchor-based approach (and vice versa). As a clinically meaningful improvement (CMI) definition is crucial to understanding the relevance of treatment on health-status measures, we estimated the CMI and the minimal CMI (MCMI) on the QEQ using an anchor-based approach and a distribution-based approach.
Materials and methods
The data source was the combined data analysis of two randomized, double-blind, placebo-controlled trials that assessed the efficacy and safety of an 16 Efficacy assessments used in this analysis included the QEQ (total score, transformed onto a 0 (worst) to 100 (best) scale) and the Erectile Function domain of the IIEF (score range, 1 (worst) to 30 (best)), which can be used to categorize ED by severity category as no ED (score X26), mild ED (22) (23) (24) (25) , mild-tomoderate ED (17) (18) (19) (20) (21) , moderate ED (11-16) and severe ED (1-10). 5, 6 Analyses were based on observed mean (s.e., 95% confidence interval (CI)) QEQ total scores within the entire intent-to-treat population (patients within the active treatment group plus the placebo group who took at least one dose of study medication and who provided sufficient efficacy data for at least one efficacy analysis during that period) at baseline, end of treatment (week 12) and their difference (change scores). The 95% CI of the QEQ mean score was calculated to incorporate the natural sampling variation in estimation of CMI.
Anchor-based approach Change in QEQ total score was derived by assessing change in ED severity category using the IIEF Erectile Function domain to determine severity. Improvement by 1 ED severity category was used to estimate CMI and MCMI in QEQ total score. Several different anchor-based methods have been described in the published literature. 11 We employed two methods: (1) scores from men who had improved by 1 ED severity category (defined as the anchor group) and (2) the difference in scores between the anchor group and the men who had no change in ED severity category (defined as the anchor group minus no-change group). Mean value and the 95% CI were derived for all men who had improved by 1 severity category to derive the anchor group estimate. Mean score for men with 'no change' was also calculated to then apply, and calculate, mean and 95% CI for the 'anchor group minus nochange' group. CMI values were proposed based on the mean change in QEQ total score. MCMI values were proposed based on the lower limit of the 95% CI of the mean change. We used the lower boundary of the 95% CI to estimate MCMI because this method incorporates the natural sampling variation in CMI and is supported by the large sample size.
Pure distribution-based approach
The pure distribution-based approach 11 
If four or more items are answered, the standardized score can still be calculated by adjusting the formula accordingly. For example, if four items had been answered, the equation would be (raw unstandardized scoreÀ4) Â 100/16. If there are more than two items missing, a score cannot be calculated.
The Quality of Erection Questionnaire is to be evaluated as a total score, which is the sum of responses to all items transformed onto a 0-100 scale. The raw score may be used informally (for example, in the clinical practice setting [18] [19] [20] From the s.e.m., the s.e. of the difference was derived as follows 21 The mean change from baseline to end of treatment in the QEQ total score for the men who improved by 1 ED severity category (the anchorbased group) was 22.4 (s.d., 2.2)-defined as the CMI; the MCMI, estimated from the lower bound of the 95% CI, was 18.0. Using the difference of this mean score of 22.4 and that from the 116 men who had no change in ED severity (the anchor group minus the no-change group), the CMI was 17.7 (s.d., 2.9) and the MCMI was 12 points (Table 2) .
According to the distribution-based analyses, the baseline 1 s.e.m. was 7.99, the end-of-treatment 1 s.e.m. was 8.22 and the s.e. of the difference was 11.46. Compared with the anchor-based MCMI estimate of 12 points (based on data from the anchor group minus the no-change group), these s.e.m. values are only slightly lower, and the s.e. of the difference value is approximately equivalent (Figure 1) .
Discussion
This study used improvement by 1 ED severity category in the IIEF Erectile Function domain score as the anchor to determine the CMI on the QEQ and used the 95% CI of the mean QEQ score to derive the MCMI. The study results estimated an MCMI that was corroborated by distribution-based methods. The slight difference in estimates between the anchor-based approach and the distribution-based approach may be caused, in part, by the different perspectives: group-based differences for the anchor-based approach versus individual-based differences for the s.e.m. and the s.e. of the difference. 
Point Estimates
Proposed MCMI (12 points) Figure 1 Approaches to estimate the MCMI on the total score of the quality of erection questionnaire. CI, confidence interval; MCMI, minimal clinically meaningful improvement; s.e.m., s.e. of measurement.
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Although anchor-based approaches to estimating MCMI are useful, 11, 14, 22 the validity of such an estimate depends on the strength of the correlation between the disease-related anchor and the PRO measure. 23 As reported previously for these data, improvement in IIEF Erectile Function domain scores showed moderate-to-high correlations with improvement in QEQ item scores (range, 0.52-0.73; Po0.0001) and with the QEQ total score (0.67; Po0.0001).
2 A limitation to our study is that we made no attempt to investigate clinically meaningful deterioration on the QEQ, which may or may not be of the same magnitude as its CMIs.
The QEQ is among an increasing list of PROs for which criteria for meaningful change in scores have been established. Others include the Parkinson's Disease Questionnaire, 17 the Functional Assessment of Cancer Therapy-Breast, 24 the Functional Assessment of Cancer Therapy-Lung, 15 the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, 25 the Overactive Bladder Questionnaire 26 and the Acne-Specific Quality of Life Questionnaire. 27 ED-specific PROs, other than the QEQ, for which criteria for meaningful change in scores have been established include the IIEF, 5 the SEAR 28 and the Erection Hardness Score. 7 The IIEF 6 provides a broad evaluation of sexual function for use in clinical trial research, the SEAR 9,10 evaluates the emotional wellbeing (self-esteem, confidence, sexual satisfaction and overall satisfaction) of men with ED and the Erection Hardness Score 7 is a targeted self-reported measure that classifies erection hardness on a single-item scale. 3 Each of these concepts is important and provides unique information for assessing ED. A recently published comparative review of seven ED-specific PROs highlights similarities and differences to aid in choosing the appropriate instrument for a specific clinical situation. 3 Unlike other ED-specific PROs, the QEQ is the only psychometrically validated PRO designed to solely and specifically evaluate satisfaction with the quality of erections. 2, 3 Satisfaction with the quality of erections is a key measure for assessing ED because 'lack of satisfaction is a prerequisite to concern or bother, the drivers of treatment-seeking behavior'.
2 Unless a man is dissatisfied with the quality of his erections, he will be unlikely to treat his ED. In the treatment of ED, erection hardness (which can be easily monitored with the Erection Hardness Score) and erection maintenance were the primary attributes sought by patients. 29, 30 On the basis of the current analyses, we believe that the proposed MCMI in QEQ scores can be used as an initial guide to interpreting change scores on the QEQ, even accounting for measurement error in individual scores. This is particularly true for populations with moderate or severe ED, given that 70% of the men in the two studies had moderate or severe ED. Repeat testing or corroboration with other psychosocial endpoints (for example, the SEAR or the Erectile Dysfunction Inventory of Treatment Satisfaction) is encouraged to enhance decision making regarding meaningful improvement or its absence. Further research in this area will only strengthen our understanding of what the MCMI and CMI are for the QEQ. Until such work has been conducted, the proposed MCMI in QEQ scores could be used for sample size estimations and could assist in interpretation of scores between and within treatment groups.
In conclusion, the QEQ is an easy-to-administer tool that has potential for use in clinical trials and clinical practice for the comprehensive evaluation of satisfaction with erection quality before and after ED therapy. Interpreting QEQ scores and establishing criteria for meaningful improvement in scores are important to understanding the relevance of outcomes on this validated health-status measure. From this study, an initial estimate of 12 points is suggested as the minimal difference between treatments that would indicate clinical importance.
